167 related articles for article (PubMed ID: 32196985)
1. Usefulness of
Sato A; Masui T; Yogo A; Uchida Y; Nakano K; Anazawa T; Nagai K; Takaori K; Nakamoto Y; Uemoto S
J Hepatobiliary Pancreat Sci; 2020 Jul; 27(7):414-420. PubMed ID: 32196985
[TBL] [Abstract][Full Text] [Related]
2. Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (
Matsumoto T; Okabe H; Yamashita YI; Yusa T; Itoyama R; Nakao Y; Yamao T; Umzaki N; Tsukamoto M; Kitano Y; Miyata T; Arima K; Nitta H; Hayashi H; Imai K; Chikamoto A; Baba H
Surg Today; 2019 Jan; 49(1):21-26. PubMed ID: 30128759
[TBL] [Abstract][Full Text] [Related]
3. Clinical Usefulness of
Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
[TBL] [Abstract][Full Text] [Related]
4. Predictive prognostic value of local and distant recurrence of F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to World Health Organization classifications (2004, 2010). Case series study.
Durán HJ; Ielpo B; Díaz E; Fabra I; Caruso R; Malavé L; Cano-Valderrama O; Garcia L; Quijano Y; Vicente E
Int J Surg; 2016 May; 29():176-82. PubMed ID: 27063856
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
6.
Satoh K; Sadowski SM; Dieckmann W; Quezado M; Nilubol N; Kebebew E; Patel D
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):714-721. PubMed ID: 27638678
[TBL] [Abstract][Full Text] [Related]
7. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
Im HJ; Oo S; Jung W; Jang JY; Kim SW; Cheon GJ; Kang KW; Chung JK; Kim EE; Lee DS
Medicine (Baltimore); 2016 May; 95(19):e3686. PubMed ID: 27175707
[TBL] [Abstract][Full Text] [Related]
9. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
[TBL] [Abstract][Full Text] [Related]
10. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions.
Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G
Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872
[TBL] [Abstract][Full Text] [Related]
11. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system.
Ezziddin S; Adler L; Sabet A; Pöppel TD; Grabellus F; Yüce A; Fischer HP; Simon B; Höller T; Biersack HJ; Nagarajah J
J Nucl Med; 2014 Aug; 55(8):1260-6. PubMed ID: 24876204
[TBL] [Abstract][Full Text] [Related]
12. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
[TBL] [Abstract][Full Text] [Related]
13. Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor.
Chan M; Schembri GP
Clin Nucl Med; 2017 Feb; 42(2):108-109. PubMed ID: 27997429
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
15. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
16.
Binderup T; Knigge U; Johnbeck CB; Loft A; Berthelsen AK; Oturai P; Mortensen J; Federspiel B; Langer SW; Kjaer A
J Nucl Med; 2021 Jun; 62(6):808-815. PubMed ID: 33067340
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
[TBL] [Abstract][Full Text] [Related]
18. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
19. Use of Diffusion-Weighted Imaging and
Noij DP; Martens RM; Koopman T; Hoekstra OS; Comans EFI; Zwezerijnen B; de Bree R; de Graaf P; Castelijns JA
Clin Oncol (R Coll Radiol); 2018 Dec; 30(12):780-792. PubMed ID: 30318343
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors.
Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H
Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
